Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of OMS103HP in ACL Reconstruction
NCT00245271Phase 3Completed
- Sponsor
- Omeros Corporation
- Start
- Oct 2004
- Primary completion
- Mar 2010
- Modality
- Large molecule
- Countries
- 1
01
Overview
A Phase 3 trial of OMS-103HP in postoperative pain, inflammation, sponsored by Omeros Corporation. Started Oct 2004; status: completed.
02
Drugs
OMS-103HP
03
Conditions
postoperative paininflammation
Beyond the preview
Go deeper on NCT00245271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245271.